A method for promoting skin basement membrane formation comprises
administering matrix metalloproteinase inhibitor or matrix
metalloproteinase inhibitor and matrix protein production promoting
agent. The matrix metalloproteinase inhibitor is
N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbuta-
namide hydrochloride.